- Home
- UAN vs MNKD Comparison
UAN vs MNKD Comparison
Compare UAN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAN | MNKD |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2008 | 2004 |
Fundamental Metrics
Financial Performance| Metric | UAN | MNKD |
|---|---|---|
| Price | $124.08 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.97 |
| AVG Volume (30 Days) | 15.0K | ★ 3.7M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $27.07 |
| Revenue Next Year | N/A | $13.65 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | 15.36 | ★ 22.23 |
| 52 Week Low | $89.20 | $2.23 |
| 52 Week High | $139.50 | $6.51 |
Technical Indicators
Market Signals| Indicator | UAN | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 63.67 |
| Support Level | $121.55 | $3.77 |
| Resistance Level | $138.77 | $4.29 |
| Average True Range (ATR) | 3.39 | 0.21 |
| MACD | -1.28 | 0.05 |
| Stochastic Oscillator | 18.19 | 90.05 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.